CHARLOTTESVILLE, Va. (WVIR) – UVA Health is asking for your help with a nationwide study to find new, effective drugs for the treatment of COVID-19.
The 15,000 people who sign up for the study will help researchers learn more about two recycled drugs that could be used to treat mild to moderate symptoms of COVID-19.
Researchers will study the effects of Fluvoxamine, an antidepressant, and Ivermectin, a pill commonly used to treat parasitic infections, in people who have tested positive for COVID-19.
The qualifications that participants must meet are that you must be over 30 years old, tested positive for COVID-19 within the last 10 days and have at least two symptoms such as fever, fatigue, body aches, loss of taste or smell
“You can be vaccinated and boosted and participate in these trials, and I certainly hope everyone gets vaccinated and boosted,” said Dr. Patrick Jackson, lead researcher on the clinical trial at UVA Health.
We asked Dr. Jackson, how a study like this could help us get to the point of the pandemic where we can live with COVID-19.
“If we can find drugs that are currently FDA-approved, cheap and readily available worldwide, I think it really brings us much closer to being able to turn COVID-19 into a mild disease where people in a way can get therapy, “he said.
Jackson said the reason the two drugs were chosen is that there have been signs of helpfulness. UVA researchers found that the antidepressant Fluvoxamine can reduce inflammation.
“[Ivermectin] used as an anti-parasitic drug, “Jackson said.” But it also turns out that in the laboratory, in petri dishes, very high doses of Ivermectin will prevent many viruses from replicating. Not everything that happens in a petri dish turns out to be helpful to a human being. But that’s part of the reason why this drug has been included in this clinical trial. “
If someone becomes part of the study, they will be sent the medicine and then fill out online surveys to track symptoms for about three months. Jackson said the benefit of this model is that it does not require constant visits to major medical centers, which he hopes will allow for a more diverse and broad population in the study.
Copyright 2022 WVIR. All rights reserved.